End Cash: The amount of cash held by the company for the given period.
Metagenomi Therapeutics, Inc. (MGX) had End Cash of $46.91M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$3.91M |
|
$-22.53M |
|
-- |
|
$3.91M |
|
$28.28M |
|
$-24.37M |
|
$1.87M |
|
$-22.49M |
|
$-22.49M |
|
$-22.53M |
|
$-22.53M |
|
$-22.53M |
|
$-22.53M |
|
$-24.37M |
|
$-23.54M |
|
37.25M |
|
37.25M |
|
$-0.59 |
|
$-0.59 |
|
| Balance Sheet Financials | |
$165.54M |
|
$12.29M |
|
$55.56M |
|
$221.10M |
|
$22.93M |
|
-- |
|
$39.57M |
|
$62.51M |
|
$158.60M |
|
$158.60M |
|
$158.60M |
|
37.62M |
|
| Cash Flow Statement Financials | |
$-88.89M |
|
$103.53M |
|
$-0.36M |
|
$32.63M |
|
|
End Cash |
$46.91M |
$14.28M |
|
$11.85M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.22 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-623.04% |
|
-623.04% |
|
-- |
|
-575.15% |
|
-576.02% |
|
$-89.43M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
12.82 |
|
7.02 |
|
-14.20% |
|
-14.20% |
|
-10.19% |
|
-14.20% |
|
$4.22 |
|
$-2.40 |
|
$-2.39 |
|